ZimVie Announces Definitive Agreement to be Acquired by ARCHIMED for $19.00 Per Share in Cash
ZimVie (Nasdaq: ZIMV), a global dental implant market leader, has announced a definitive agreement to be acquired by healthcare-focused investment firm ARCHIMED in an all-cash transaction valued at approximately $730 million.
Under the agreement, ZIMV shareholders will receive $19.00 per share in cash, representing a 99% premium to the company's 90-day volume-weighted average price of $9.57. The transaction, unanimously approved by ZimVie's Board of Directors, is expected to close by year-end 2025, subject to stockholder and regulatory approvals.
The company has initiated a 40-day go-shop period through August 29, 2025, during which it may solicit alternative proposals. Upon completion, ZimVie will become private and delist from NASDAQ.
ZimVie (Nasdaq: ZIMV), leader globale nel mercato degli impianti dentali, ha annunciato un accordo definitivo per essere acquisita dalla societ脿 di investimenti nel settore sanitario ARCHIMED in un鈥檕perazione interamente in contanti del valore di circa 730 milioni di dollari.
Secondo l鈥檃ccordo, gli azionisti di ZIMV riceveranno 19,00 dollari per azione in contanti, pari a un premio del 99% rispetto al prezzo medio ponderato per il volume degli ultimi 90 giorni di 9,57 dollari. L鈥檕perazione, approvata all鈥檜nanimit脿 dal Consiglio di Amministrazione di ZimVie, dovrebbe concludersi entro la fine del 2025, subordinatamente alle approvazioni degli azionisti e degli enti regolatori.
L鈥檃zienda ha avviato un periodo di ricerca di offerte alternative di 40 giorni fino al 29 agosto 2025, durante il quale potr脿 valutare proposte concorrenti. Al completamento dell鈥檕perazione, ZimVie diventer脿 una societ脿 privata e sar脿 esclusa dal listino NASDAQ.
ZimVie (Nasdaq: ZIMV), l铆der global en el mercado de implantes dentales, ha anunciado un acuerdo definitivo para ser adquirida por la firma de inversi贸n enfocada en salud ARCHIMED en una transacci贸n totalmente en efectivo valorada en aproximadamente 730 millones de d贸lares.
Seg煤n el acuerdo, los accionistas de ZIMV recibir谩n 19.00 d贸lares por acci贸n en efectivo, lo que representa una prima del 99% sobre el precio promedio ponderado por volumen de los 煤ltimos 90 d铆as de 9.57 d贸lares. La transacci贸n, aprobada por unanimidad por la Junta Directiva de ZimVie, se espera que se cierre para finales de 2025, sujeto a la aprobaci贸n de los accionistas y reguladores.
La compa帽铆a ha iniciado un periodo de b煤squeda de ofertas alternativas de 40 d铆as hasta el 29 de agosto de 2025, durante el cual podr谩 solicitar propuestas alternativas. Al completarse, ZimVie se volver谩 privada y se retirar谩 del NASDAQ.
ZimVie (雮橃姢雼�: ZIMV)電� 旮�搿滊矊 旃橁臣 鞛勴攲霝�韸� 鞁滌灔鞚� 靹犽憪欤检瀽搿�, 項姢旒�鞏� 鞝勲 韴瀽 須岇偓鞚� ARCHIMED鞐� 鞎� 7鞏� 3觳滊 雼煬 攴滊鞚� 鞝勳暋 順勱笀 瓯半灅搿� 鞚胳垬霅滊嫟電� 頇曥爼 瓿勳暯鞚� 氚滍憸頄堨姷雼堧嫟.
瓿勳暯鞐� 霐半澕 ZIMV 欤检＜霌れ潃 欤茧嫻 19.00雼煬鞚� 順勱笀鞚� 氚涥矊 霅橂┌, 鞚措姅 斓滉芳 90鞚缄皠 瓯半灅霟� 臧�欷� 韽夑窢臧� 9.57雼煬鞐� 雽�頃� 99% 頂勲Μ氙胳梽鞐� 頃措嫻頃╇媹雼�. 鞚� 瓯半灅電� ZimVie 鞚挫偓須� 鞝勳洂 霃欖潣搿� 鞀轨澑霅橃棃鞙茧┌, 欤检＜ 氚� 攴滌牅 雼龟淡鞚� 鞀轨澑鞚� 臁瓣贝鞙茧 2025雲� 毵愱箤歆� 鞕勲霅� 鞓堨爼鞛呺媹雼�.
须岇偓电� 2025雲� 8鞗� 29鞚缄箤歆� 40鞚缄皠鞚� 於旉皜 鞝滌晥 鞖旍箔 旮瓣皠鞚� 鞁滌瀾頄堨溂氅�, 鞚� 旮瓣皠 霃欖晥 雽�觳� 鞝滌晥鞚� 氚涭潉 靾� 鞛堨姷雼堧嫟. 瓯半灅 鞕勲 頉� ZimVie電� 牍勳儊鞛� 須岇偓搿� 鞝勴櫂霅橁碃 雮橃姢雼レ棎靹� 靸侅灔 韽愳霅╇媹雼�.
ZimVie (Nasdaq : ZIMV), leader mondial sur le march茅 des implants dentaires, a annonc茅 un accord d茅finitif pour 锚tre rachet茅 par la soci茅t茅 d鈥檌nvestissement sp茅cialis茅e dans la sant茅 ARCHIMED dans le cadre d鈥檜ne transaction enti猫rement en esp猫ces d鈥檜ne valeur d鈥檈nviron 730 millions de dollars.
Conform茅ment 脿 l鈥檃ccord, les actionnaires de ZIMV recevront 19,00 dollars par action en esp猫ces, ce qui repr茅sente une prime de 99% par rapport au prix moyen pond茅r茅 par le volume sur 90 jours de 9,57 dollars. La transaction, approuv茅e 脿 l鈥檜nanimit茅 par le conseil d鈥檃dministration de ZimVie, devrait 锚tre finalis茅e d鈥檌ci la fin de l鈥檃nn茅e 2025, sous r茅serve des approbations des actionnaires et des autorit茅s r茅glementaires.
L鈥檈ntreprise a lanc茅 une p茅riode de recherche d鈥檕ffres concurrentes de 40 jours jusqu鈥檃u 29 ao没t 2025, durant laquelle elle pourra solliciter des propositions alternatives. Une fois l鈥檕p茅ration finalis茅e, ZimVie deviendra priv茅e et sera retir茅e du NASDAQ.
ZimVie (Nasdaq: ZIMV), ein weltweit f眉hrendes Unternehmen im Bereich Zahnimplantate, hat eine endg眉ltige Vereinbarung 眉ber die 脺bernahme durch die auf Gesundheitswesen spezialisierte Investmentfirma ARCHIMED in einer vollst盲ndig bar bezahlten Transaktion im Wert von etwa 730 Millionen US-Dollar bekannt gegeben.
Gem盲脽 der Vereinbarung erhalten die ZIMV-Aktion盲re 19,00 US-Dollar pro Aktie in bar, was einer Pr盲mie von 99% gegen眉ber dem volumengewichteten Durchschnittskurs der letzten 90 Tage von 9,57 US-Dollar entspricht. Die Transaktion, die vom Vorstand von ZimVie einstimmig genehmigt wurde, soll bis Ende 2025 abgeschlossen sein, vorbehaltlich der Zustimmung der Aktion盲re und der Regulierungsbeh枚rden.
Das Unternehmen hat eine 40-t盲gige Go-Shop-Phase bis zum 29. August 2025 eingeleitet, in der alternative Angebote eingeholt werden k枚nnen. Nach Abschluss wird ZimVie privat und von der NASDAQ genommen.
- All-cash transaction offering 99% premium to 90-day VWAP
- Strategic partnership with healthcare-focused investor to expand dental technology globally
- Unanimous board approval indicates strong confidence in the deal
- 40-day go-shop period allows for potential superior offers
- Shareholders will lose public market exposure after delisting
- Transaction subject to regulatory and shareholder approval risks
- Deal completion not expected until year-end 2025
Insights
ZimVie's acquisition by ARCHIMED at a 99% premium offers shareholders immediate significant value while addressing potential growth challenges.
The $19.00 per share all-cash offer from ARCHIMED represents a substantial
The unanimous board approval indicates strong internal confidence that this deal maximizes shareholder value. The transaction includes a 40-day "go-shop" period through August 29, allowing ZimVie to solicit potentially better offers, providing shareholders with protection against undervaluation.
For current shareholders, this deal delivers immediate and significant value appreciation without the execution risks of ZimVie's standalone growth strategy. Taking the company private removes quarterly performance pressures and reporting requirements, potentially allowing management to focus on longer-term innovation and market expansion under ARCHIMED's healthcare-focused ownership.
ARCHIMED's exclusive healthcare focus suggests they identified specific growth levers in ZimVie's dental implant business that could benefit from strategic investment and industry expertise. The firm likely sees opportunities to expand ZimVie's global reach and technological innovation that weren't fully realized under public ownership.
This acquisition follows a broader trend of private equity targeting undervalued healthcare technology companies with stable customer bases and recurring revenue models. The substantial premium indicates ARCHIMED's strong conviction in ZimVie's long-term potential despite current market valuation challenges.
Transaction expected to close by year-end 2025
PALM BEACH GARDENS, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (鈥淶imVie鈥�) (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (鈥淎RCHIMED鈥�), an investment firm focused exclusively on healthcare industries.
Under the terms of the merger agreement, ZimVie stockholders will receive
鈥淭his transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years,鈥� said Vafa Jamali, Chairman of the Board and Chief Executive Officer of ZimVie. 鈥淧artnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally.鈥�
鈥淲e鈥檙e excited to partner with ZimVie and its talented team,鈥� said Andr茅-Michel Ballester, Managing Partner, at ARCHIMED. 鈥淭he company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter.鈥�
Approvals and Timing
The Board of Directors of ZimVie has unanimously approved the transaction. The transaction is expected to close by year-end 2025, subject to the satisfaction of customary closing conditions, including approval by ZimVie鈥檚 stockholders and applicable regulatory approvals. The transaction is not subject to a financing condition. Prior to the deal鈥檚 closing, ZimVie is operating business as usual, separately from ARCHIMED.
Upon completion of the transaction, ZimVie will become a privately held company and ZimVie鈥檚 shares will no longer be listed on the NASDAQ stock exchange.
Go-Shop Period
Under the terms of the merger agreement, ZimVie, with the assistance of Centerview Partners, its financial advisor, may solicit proposals from third parties for a period of 40 days continuing through midnight, New York City time, on August 29, 2025. ZimVie does not anticipate disclosing any developments regarding this process unless and until its Board of Directors makes a decision with respect to a potential superior proposal. There can be no assurance that the solicitation process will result in a superior proposal.
Advisors
Centerview Partners is serving as exclusive financial advisor to ZimVie, and Cravath, Swaine & Moore LLP is serving as legal advisor. UBS Investment Bank is serving as exclusive financial advisor to ARCHIMED, and Latham & Watkins LLP is serving as legal advisor.
About ZimVie
ZimVie is a global life sciences leader in the dental implant market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at聽. Follow @ZimVie on聽,听,听, or聽.
About ARCHIMED
With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages
Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning ZimVie鈥檚 expectations, plans, intentions, strategies or prospects, including expected benefits of the proposed transaction. Generally, the words 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渆xpects,鈥� 鈥渂elieves,鈥� 鈥渁nticipates,鈥� 鈥減lans,鈥� 鈥渆stimates,鈥� 鈥減rojects,鈥� 鈥渁ssumes,鈥� 鈥済uides,鈥� 鈥渢argets,鈥� 鈥渇orecasts,鈥� 鈥渟ees,鈥� 鈥渟eeks,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥減redicts,鈥� 鈥減otential,鈥� 鈥渟trategy,鈥� 鈥渇uture,鈥� 鈥渙pportunity,鈥� 鈥渨ork toward,鈥� 鈥渋ntends,鈥� 鈥済uidance,鈥� 鈥渃onfidence,鈥� 鈥減ositioned,鈥� 鈥渄esign,鈥� 鈥渟trive,鈥� 鈥渃ontinue,鈥� 鈥渢rack,鈥� 鈥渓ook forward to鈥� and similar expressions used in this release are intended to identify forward-looking statements. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements.
Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements.
These risks, uncertainties and changes in circumstances include, but are not limited to: (i) the risk that the proposed transaction may not be completed in a timely manner or at all; (ii) the failure to receive, on a timely basis or otherwise, the required approvals of the proposed transaction by ZimVie鈥檚 stockholders; (iii) the possibility that any or all of the various conditions to the consummation of the proposed transaction may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (iv) the possibility that competing offers or acquisition proposals for ZimVie will be made; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the proposed transaction, including in circumstances which would require ZimVie to pay a termination fee; (vi) the effect of the announcement or pendency of the proposed transaction on ZimVie鈥檚 ability to attract, motivate or retain key executives and employees, its ability to maintain relationships with its customers, suppliers and other business counterparties, or its operating results and business generally; (vii) risks related to the proposed transaction diverting management鈥檚 attention from ZimVie鈥檚 ongoing business operations; (viii) the risk of stockholder litigation in connection with the proposed transaction, including resulting expense or delay; and (ix) (A) any other risks discussed in ZimVie鈥檚 Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the 鈥淎nnual Report鈥�) and ZimVie鈥檚 Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the 鈥淨uarterly Report鈥�) filed by ZimVie with the Securities and Exchange Commission (the 鈥淪EC鈥�), and, in particular, the risk factors set forth under the headings 鈥淩isk Factors鈥� and 鈥淢anagement鈥檚 Discussion and Analysis of Financial Condition and Results of Operations鈥� in the Annual Report and the Quarterly Report and (B) other risk factors identified from time to time in other filings with the SEC. Filings with the SEC are available on the SEC鈥檚 website at .
Forward-looking statements speak only as of the date they are made, and ZimVie disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this release.
Participants in the Solicitation
ZimVie and its directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be 鈥減articipants鈥� in the solicitation of proxies from stockholders of ZimVie in connection with the proposed transaction. Information about ZimVie鈥檚 directors and executive officers is set forth in ZimVie鈥檚 Proxy Statement on Schedule 14A for its 2025 Annual Meeting of Shareholders, which was filed with the SEC on March 25, 2025 (the 鈥�2025 Proxy鈥�) (and available here). Please refer to the sections entitled 鈥淐ompensation of Non-Employee Directors,鈥� 鈥淓xecutive Compensation鈥� and 鈥淪ecurity Ownership of Directors and Executive Officers鈥� in the 2025 Proxy. To the extent holdings of ZimVie鈥檚 securities by its directors or executive officers have changed since the amounts set forth in the 2025 Proxy, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, including the Form 4s filed by: Richard Heppenstall on March 11, 2025 and May 19, 2025; Vafa Jamali on March 11, 2025, March 27, 2025, March 27, 2025, April 3, 2025 and May 19, 2025; Indraneel Kanaglekar on March 11, 2025, May 19, 2025 and July 3, 2025; Heather Kidwell on March 11, 2025 and May 19, 2025; Richard Kuntz on April 2, 2025, May 9, 2025 and July 2, 2025; Vinit K. Asar on May 9, 2025; Sally Crawford on May 9, 2025; and Karen Matusinec on May 9, 2025. Additional information concerning the interests of ZimVie鈥檚 participants in the solicitation, which may, in some cases, be different than those of ZimVie鈥檚 stockholders generally, will be set forth in ZimVie鈥檚 proxy statement relating to the proposed transaction when it becomes available.
Additional Information and Where to Find It
This release may be deemed to be solicitation material in respect of the proposed acquisition of ZimVie by ARCHIMED. In connection with the proposed transaction, ZimVie intends to file relevant materials with the SEC, including ZimVie鈥檚 proxy statement in preliminary and definitive form. INVESTORS AND STOCKHOLDERS OF ZIMVIE ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING ZIMVIE鈥橲 PROXY STATEMENT (IF AND WHEN AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders are or will be able to obtain the documents (if and when available) free of charge at the SEC鈥檚 website at , or free of charge from ZimVie in the 鈥淚nvestor Relations鈥� section of ZimVie鈥檚 website, which may be accessed at , or upon request from ZimVie鈥檚 Investor Relations contacts.
Media Contact Information:
ZimVie
Grace Flowers 鈥�
(561) 319-6130
Investor Contact Information:
Gilmartin Group LLC
Webb Campbell 鈥�
FAQ
What is the acquisition price for ZimVie (ZIMV) stock?
When will the ZimVie (ZIMV) acquisition by ARCHIMED close?
What premium does the ZIMV acquisition offer to shareholders?
Will ZimVie (ZIMV) remain publicly traded after the acquisition?
Can ZimVie (ZIMV) accept other acquisition offers?
